Evommune EVMN
NYSE EVMN
$5.18 -0.20 (-3.72%)
As of: Oct 21, 2026 · 3:59 PM EDT

Evommune (EVMN) Revenue (2025)

Updated

Evommune (EVMN) reported Revenue of $13 million for FY2025, up 85.7% from $7 million in FY2024.

Analysis

Evommune (EVMN) Revenue (2025) Analysis & Trends

  • According to Business Quant data, Revenue came in at $7 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 22.97 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 25.31 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 16.99 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 16.61 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 14.41 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 15.38 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 10.05 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 7.80 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 15.03 Bn
10 Evommune 186.46 Mn -451.06 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 10.00 Mn
Mar 31, 2025 3.00 Mn
API Access

Evommune Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=revenue&ticker=EVMN&period=max&api_key=YOUR_API_KEY